These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 28745329)

  • 1. Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients.
    Ruberti S; Bianchi E; Guglielmelli P; Rontauroli S; Barbieri G; Tavernari L; Fanelli T; Norfo R; Pennucci V; Fattori GC; Mannarelli C; Bartalucci N; Mora B; Elli L; Avanzini MA; Rossi C; Salmoiraghi S; Zini R; Salati S; Prudente Z; Rosti V; Passamonti F; Rambaldi A; Ferrari S; Tagliafico E; Vannucchi AM; Manfredini R
    Leukemia; 2018 Feb; 32(2):438-449. PubMed ID: 28745329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of miR-34a-5p in Hematopoietic Progenitor Cells Proliferation and Fate Decision: Novel Insights into the Pathogenesis of Primary Myelofibrosis.
    Bianchi E; Ruberti S; Rontauroli S; Guglielmelli P; Salati S; Rossi C; Zini R; Tagliafico E; Vannucchi AM; Manfredini R
    Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28098757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GATA1 downregulation in prefibrotic and fibrotic stages of primary myelofibrosis and in the myelofibrotic progression of other myeloproliferative neoplasms.
    Sangiorgio VFI; Nam A; Chen Z; Orazi A; Tam W
    Leuk Res; 2021 Jan; 100():106495. PubMed ID: 33360878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myelofibrotic transformations of polycythemia vera and essential thrombocythemia are morphologically, biologically, and prognostically indistinguishable from primary myelofibrosis.
    Sangle N; Cook J; Perkins S; Teman CJ; Bahler D; Hickman K; Wilson A; Prchal J; Salama ME
    Appl Immunohistochem Mol Morphol; 2014 Oct; 22(9):663-8. PubMed ID: 24897074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The expression of lysyl-oxidase gene family members in myeloproliferative neoplasms.
    Tadmor T; Bejar J; Attias D; Mischenko E; Sabo E; Neufeld G; Vadasz Z
    Am J Hematol; 2013 May; 88(5):355-8. PubMed ID: 23494965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heterogeneity of the bone marrow niche in patients with myeloproliferative neoplasms: ActivinA secretion by mesenchymal stromal cells correlates with the degree of marrow fibrosis.
    Rambaldi B; Diral E; Donsante S; Di Marzo N; Mottadelli F; Cardinale L; Dander E; Isimbaldi G; Pioltelli P; Biondi A; Riminucci M; D'Amico G; Elli EM; Pievani A; Serafini M
    Ann Hematol; 2021 Jan; 100(1):105-116. PubMed ID: 33089365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MYB controls erythroid versus megakaryocyte lineage fate decision through the miR-486-3p-mediated downregulation of MAF.
    Bianchi E; Bulgarelli J; Ruberti S; Rontauroli S; Sacchi G; Norfo R; Pennucci V; Zini R; Salati S; Prudente Z; Ferrari S; Manfredini R
    Cell Death Differ; 2015 Dec; 22(12):1906-21. PubMed ID: 25857263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased Dkk3 protein expression in platelets and megakaryocytes of patients with myeloproliferative neoplasms.
    Medinger M; Tzankov A; Kern J; Pircher A; Hermann M; Ott HW; Gastl G; Untergasser G; Gunsilius E
    Thromb Haemost; 2011 Jan; 105(1):72-80. PubMed ID: 20978717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombospondin-1 (TSP-1) in primary myelofibrosis (PMF) - a megakaryocyte-derived biomarker which largely discriminates PMF from essential thrombocythemia.
    Muth M; Engelhardt BM; Kröger N; Hussein K; Schlué J; Büsche G; Kreipe HH; Bock O
    Ann Hematol; 2011 Jan; 90(1):33-40. PubMed ID: 20625903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. β-catenin and PPAR-γ levels in bone marrow of myeloproliferative neoplasm: an immunohistochemical and ultrastructural study.
    Subotički T; Mitrović Ajtić O; Mićić M; Kravić Stevović T; Đikić D; Diklić M; Leković D; Gotić M; Čokić VP
    Ultrastruct Pathol; 2018; 42(6):498-507. PubMed ID: 30582392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Macrophage frequency in the bone marrow correlates with morphologic subtype of myeloproliferative neoplasm.
    Molitor DCA; Boor P; Buness A; Schneider RK; Teichmann LL; Körber RM; Horvath GL; Koschmieder S; Gütgemann I
    Ann Hematol; 2021 Jan; 100(1):97-104. PubMed ID: 33104881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of beta-catenin in chronic myeloproliferative disorders.
    Jauregui MP; Sanchez SR; Ewton AA; Rice L; Perkins SL; Dunphy CH; Chang CC
    Hum Pathol; 2008 Oct; 39(10):1454-8. PubMed ID: 18619646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F.
    Shide K; Shimoda HK; Kumano T; Karube K; Kameda T; Takenaka K; Oku S; Abe H; Katayose KS; Kubuki Y; Kusumoto K; Hasuike S; Tahara Y; Nagata K; Matsuda T; Ohshima K; Harada M; Shimoda K
    Leukemia; 2008 Jan; 22(1):87-95. PubMed ID: 18033315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Thrombocythemia Vera Study Group.
    Michiels JJ; Juvonen E
    Semin Thromb Hemost; 1997; 23(4):339-47. PubMed ID: 9263350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased CXCL4 expression in hematopoietic cells links inflammation and progression of bone marrow fibrosis in MPN.
    Gleitz HFE; Dugourd AJF; Leimkühler NB; Snoeren IAM; Fuchs SNR; Menzel S; Ziegler S; Kröger N; Triviai I; Büsche G; Kreipe H; Banjanin B; Pritchard JE; Hoogenboezem R; Bindels EM; Schumacher N; Rose-John S; Elf S; Saez-Rodriguez J; Kramann R; Schneider RK
    Blood; 2020 Oct; 136(18):2051-2064. PubMed ID: 32726410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations.
    Boveri E; Passamonti F; Rumi E; Pietra D; Elena C; Arcaini L; Pascutto C; Castello A; Cazzola M; Magrini U; Lazzarino M
    Br J Haematol; 2008 Jan; 140(2):162-8. PubMed ID: 18028479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcription factor 3 is dysregulated in megakaryocytes in myelofibrosis.
    Collinson RJ; Wilson L; Boey D; Ng ZY; Mirzai B; Chuah HS; Howman R; Grove CS; Malherbe JAJ; Leahy MF; Linden MD; Fuller KA; Erber WN; Guo BB
    Platelets; 2024 Dec; 35(1):2304173. PubMed ID: 38303515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
    Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
    Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beta-thromboglobulin content in megakaryocytes of patients with myeloproliferative diseases.
    Grossi A; Vannucchi AM; Rafanelli D; Filimberti E; Rossi Ferrini P
    Thromb Res; 1986 Aug; 43(3):367-74. PubMed ID: 2426823
    [No Abstract]   [Full Text] [Related]  

  • 20. Primary myelofibrosis is the most frequent myeloproliferative neoplasm associated with del(5q): clinicopathologic comparison of del(5q)-positive and -negative cases.
    Santana-Davila R; Tefferi A; Holtan SG; Ketterling RP; Dewald GW; Knudson RA; Steensma DP; Chen D; Hoyer JD; Hanson CA
    Leuk Res; 2008 Dec; 32(12):1927-30. PubMed ID: 18538839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.